Subcutaneous Amivantamab for NSCLC Could Benefit Patients, Practices: Balazs Halmos, MD

Balazs Halmos, MD, discussed the potential impact of subcutaneous amivantamab for patients with EGFR-mutated NSCLC. Halmos oversees the thoracic clinical trials program of novel clinical studies at the Montefiore Albert Einstein Cancer Center.

This transcript has been lightly edited; captions are auto-generated.

Transcript

From a regulatory and reimbursement perspective, are there unique considerations that could affect uptake of a subcutaneous amivantamab formulation?

I'm sure there are. That's not necessarily my focus, but I do believe that the subcutaneous formulation might be approved by the FDA in the coming weeks to months. Of course, I don't have any specific insights, but we're hopeful. I think when that happens, from then on, each treatment team and each practice has to kind of consider how to quickly integrate this into the practices. This will be huge for your patients, as it is a much easier, much more convenient, and much safer administration. I do believe that this will also help in terms of saving chair time so that other patients can receive their treatment, also at a faster rate. I think everybody will win.